Acumen Pharmaceuticals, Inc.

NasdaqGS:ABOS Stock Report

Market Cap: US$114.2m

Acumen Pharmaceuticals Management

Management criteria checks 2/4

Acumen Pharmaceuticals' CEO is Dan O'Connell, appointed in Dec 2014, has a tenure of 10.08 years. total yearly compensation is $3.93M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth $48.42K. The average tenure of the management team and the board of directors is 3.2 years and 6.3 years respectively.

Key information

Dan O'Connell

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage15.2%
CEO tenure10.1yrs
CEO ownership0.04%
Management average tenure3.2yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 30

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Dan O'Connell's remuneration changed compared to Acumen Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$82m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$598k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$570k

-US$43m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$1mUS$525k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$92m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$336kUS$240k

-US$7m

Compensation vs Market: Dan's total compensation ($USD3.93M) is above average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan O'Connell (54 yo)

10.1yrs

Tenure

US$3,930,011

Compensation

Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. si...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel O'Connell
CEO & Director10.1yrsUS$3.93m0.042%
$ 48.4k
Matt Zuga
CFO & Chief Business Officer3.7yrsUS$1.61m0.14%
$ 157.9k
Derek Meisner
Chief Legal Officer & Corporate Secretary2.3yrsUS$1.48m0%
$ 0
James Doherty
President & Chief Development Officerless than a yearno datano data
Grant Krafft
Co-Founder29yrsUS$42.00kno data
Caleb Finch
Co-Founderno datano datano data
William Klein
Co-Founderno datano datano data
Russell Barton
Chief Operating Officer4yrsUS$223.68k0.16%
$ 184.0k
Kelly Carranza
Vice President1.5yrsno datano data
Alex Braun
VP & Head of Investor Relations2.3yrsno datano data
Robyn Moxon
Associate Director of Communications2.7yrsno datano data
Julie Bockenstette
Executive VP & Head of Human Resources4yrsno datano data

3.2yrs

Average Tenure

55yo

Average Age

Experienced Management: ABOS's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel O'Connell
CEO & Director18.8yrsUS$3.93m0.042%
$ 48.4k
Michael Weiner
Member of Clinical & Scientific Advisory Boardno datano datano data
Colin Masters
Member of Clinical & Scientific Advisory Boardno datano datano data
Jeffrey Cummings
Member of Clinical & Scientific Advisory Boardno datano datano data
Sean Stalfort
Independent Chairman of the Board6.3yrsUS$173.52k0.51%
$ 577.4k
Kimberlee Drapkin
Independent Director2.8yrsUS$152.27k0%
$ 0
Steven DeKosky
Member of Clinical & Scientific Advisory Boardno datano datano data
Jeffrey L. Ives
Independent Director10.7yrsUS$141.02k0%
$ 0
Reisa Sperling
Member of Clinical & Scientific Advisory Boardno datano datano data
Cynthia Lemere
Member of Clinical & Scientific Advisory Boardno datano datano data
Laura Stoppel
Independent Director4.2yrsUS$147.52k0%
$ 0
Stephen Salloway
Member of Clinical & Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

64.5yo

Average Age

Experienced Board: ABOS's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 06:24
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acumen Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Jason ZemanskyBofA Global Research
Thomas ShraderBTIG